Single-domain antibodies for biomedical applications

References

• Aggarwal SR. What's fueling the biotech engine – 2010 to 2011. Nat Biotechnol 2011;29:1083–1089
   PubMed Web of Science ®Google Scholar
• Aggarwal SR. What's fueling the biotech engine – 2011 to 2012. Nat Biotechnol 2012;30:1191–1197
   PubMed Web of Science ®Google Scholar
• Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012;12:615–622
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413–415
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013;5:1–4
   PubMed Web of Science ®Google Scholar
• Dübel S. Recombinant therapeutic antibodies. Appl Microbiol Biotechnol 2007;74:723–729
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs 2015;7:1–8
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536–544
   PubMed Web of Science ®Google Scholar
• Vaneycken I, D'Huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol 2011;22:877–881
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10:167–175
   PubMed Web of Science ®Google Scholar
• Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006;3:53–70
   PubMedGoogle Scholar
• Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects. Q J Nucl Med Mol Imaging 2004;48:317–325
   PubMed Web of Science ®Google Scholar
• Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422–428
   PubMed Web of Science ®Google Scholar
• Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates - a new wave of cancer drugs. Bioorg Med Chem Lett 2014;24:5357–5363
   PubMed Web of Science ®Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012;17:583–590
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2014;93:290–296
   PubMed Web of Science ®Google Scholar
• Kolmar H. Natural and engineered cystine knot miniproteins for diagnostic and therapeutic applications. Curr Pharm Des 2011;17:4329–4336
   PubMed Web of Science ®Google Scholar
• Richter A, Eggenstein E, Skerra A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett 2014;588:213–218
   PubMed Web of Science ®Google Scholar
• Boersma YL, Plückthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011;22:849–857
   PubMed Web of Science ®Google Scholar
• Ying T, Gong R, Ju TW, et al. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta 2014;1844:1977–1982
   PubMed Web of Science ®Google Scholar
• Wozniak-Knopp G, Bartl S, Bauer A, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010;23:289–297
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446–448
   PubMed Web of Science ®Google Scholar
• Greenberg AS, Avila D, Hughes M, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995;374:168–173
   PubMed Web of Science ®Google Scholar
• Davies J, Riechmann L. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng 1996;9:531–537
   PubMedGoogle Scholar
• Holt LJ, Herring C, Jespers LS, et al. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003;21:484–490
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs 2009;1:26–28
   PubMed Web of Science ®Google Scholar
• van der Linden RH, Frenken LG, de Geus B, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999;1431:37–46
   PubMed Web of Science ®Google Scholar
• Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009;198:157–174
   PubMed Web of Science ®Google Scholar
• Conrath K, Vincke C, Stijlemans B, et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 2005;350:112–125
   PubMed Web of Science ®Google Scholar
• Zarschler K, Witecy S, Kapplusch F, et al. High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. Microb Cell Fact 2013;12:97
   PubMed Web of Science ®Google Scholar
• Li F, Vijayasankaran N, Shen AY, et al. Cell culture processes for monoclonal antibody production. MAbs 2010;2:466–479
   PubMed Web of Science ®Google Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997;414:521–526
   PubMed Web of Science ®Google Scholar
• Ryckaert S, Pardon E, Steyaert J, Callewaert N. Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. J Biotechnol 2010;145:93–98
   PubMed Web of Science ®Google Scholar
• Yau KY, Groves MA, Li S, et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J Immunol Methods 2003;281:161–175
   PubMed Web of Science ®Google Scholar
• Fleetwood F, Devoogdt N, Pellis M, et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell Mol Life Sci 2013;70:1081–1093
   PubMed Web of Science ®Google Scholar
• Monegal A, Ami D, Martinelli C, et al. Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. Protein Eng Des Sel 2009;22:273–280
   PubMed Web of Science ®Google Scholar
• Goldman ER, Anderson GP, Liu JL, et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem. 2006;78:8245–8255
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009;284:3273–3284
   PubMed Web of Science ®Google Scholar
• Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603–3610
   PubMed Web of Science ®Google Scholar
• Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release 2012;161:429–445
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993–996
   PubMed Web of Science ®Google Scholar
• Jahnichen S, Blanchetot C, Maussang D, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 2010;107:20565–20570
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujic-Delic A, Descamps FJ, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 2013;288:29562–29572
   PubMed Web of Science ®Google Scholar
• Habib I, Smolarek D, Hattab C, et al. V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. Anal Biochem 2013;438:82–89
   PubMed Web of Science ®Google Scholar
• Zhu M, Gong X, Hu Y, et al. Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. J Transl Med 2014;12:352
   PubMed Web of Science ®Google Scholar
• Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012;72:4165–4177
   PubMed Web of Science ®Google Scholar
• Zielonka S, Empting M, Grzeschik J, et al. Structural insights and biomedical potential of IgNAR scaffolds from sharks. MAbs 2015;7:15–25
   PubMed Web of Science ®Google Scholar
• Barelle C, Gill DS, Charlton K. Shark novel antigen receptors-the next generation of biologic therapeutics? Adv Exp Med Biol 2009;655:49–62
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Dooley H, Flajnik MF, Wilson IA. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 2004;305:1770–1773
   PubMed Web of Science ®Google Scholar
• Dooley H, Stanfield RL, Brady RA, Flajnik MF. First molecular and biochemical analysis of in vivo affinity maturation in an ectothermic vertebrate. Proc Natl Acad Sci USA 2006;103:1846–1851
   PubMed Web of Science ®Google Scholar
• Zielonka S, Könning D, Grzeschik J, et al. The shark strikes twice: hypervariable loop 2 of shark IgNAR antibody variable domains and its potential to function as an autonomous paratope. Mar Biotechnol (NY) 2015;17:386–392
   PubMed Web of Science ®Google Scholar
• Diaz M, Stanfield RL, Greenberg AS, Flajnik MF. Structural analysis, selection, and ontogeny of the shark new antigen receptor (IgNAR): identification of a new locus preferentially expressed in early development. Immunogenetics 2002;54:501–512
   PubMed Web of Science ®Google Scholar
• Kovalenko OV, Olland A, Piche-Nicholas N, et al. Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis. J Biol Chem 2013;288:17408–17419
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Dooley H, Verdino P, et al. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J Mol Biol 2007;367:358–372
   PubMed Web of Science ®Google Scholar
• Streltsov VA, Carmichael JA, Nuttall SD. Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci 2005;14:2901–2909
   PubMed Web of Science ®Google Scholar
• Simmons DP, Streltsov VA, Dolezal O, et al. Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures. Proteins 2008;71:119–130
   PubMed Web of Science ®Google Scholar
• Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol 2011;9:e1001120
   PubMed Web of Science ®Google Scholar
• Streltsov VA, Varghese JN, Carmichael JA, et al. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci USA 2004;101:12444–12449
   PubMed Web of Science ®Google Scholar
• Henderson KA, Streltsov VA, Coley AM, et al. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 2007;15:1452–1466
   PubMed Web of Science ®Google Scholar
• Feige MJ, Gräwert MA, Marcinowski M, et al. The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins. Proc Natl Acad Sci USA 2014;111:8155–8160
   PubMed Web of Science ®Google Scholar
• Liu JL, Anderson GP, Delehanty JB, et al. Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library. Mol Immunol 2007;44:1775–1783
   PubMed Web of Science ®Google Scholar
• Goodchild SA, Dooley H, Schoepp RJ, et al. Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries. Mol Immunol 2011;48:2027–2037
   PubMed Web of Science ®Google Scholar
• Zielonka S, Weber N, Becker S, et al. Shark attack: high affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation. J Biotechnol 2014;191:236–245
   PubMed Web of Science ®Google Scholar
• Kovaleva M, Ferguson L, Steven J, et al. Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development. Expert Opin Biol Ther 2014;14:1527–1539
   PubMed Web of Science ®Google Scholar
• Muller MR, Saunders K, Grace C, et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. MAbs 2012;4:673–685
   PubMed Web of Science ®Google Scholar
• Simmons DP, Abregu FA, Krishnan UV, et al. Dimerisation strategies for shark IgNAR single domain antibody fragments. J Immunol Methods 2006;315:171–184
   PubMed Web of Science ®Google Scholar
• Uth C, Zielonka S, Hörner S, et al. A chemoenzymatic approach to protein immobilization onto crystalline cellulose nanoscaffolds. Angew Chem Int Ed Engl 2014;53:12618–12623
   PubMed Web of Science ®Google Scholar
• Streltsov VA, Varghese JN, Masters CL, Nuttall SD. Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 2011;31:1419–1426
   PubMed Web of Science ®Google Scholar
• Walsh R, Nuttall S, Revill P, et al. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology 2011;411:132–141
   PubMed Web of Science ®Google Scholar
• Liu JL, Anderson GP, Goldman ER. Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library. BMC Biotechnol 2007;7:78
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Humberstone KS, Krishnan UV, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004;55:187–197
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Krishnan UV, Doughty L, et al. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur J Biochem 2003;270:3543–3554
   PubMedGoogle Scholar
• Ohtani M, Hikima J, Jung TS, et al. Variable domain antibodies specific for viral hemorrhagic septicemia virus (VHSV) selected from a randomized IgNAR phage display library. Fish Shellfish Immunol 2013;34:724–728
   PubMed Web of Science ®Google Scholar
• Bojalil R, Mata-Gonzalez MT, Sanchez-Munoz F, et al. Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock. BMC Immunol 2013;14:17
   PubMed Web of Science ®Google Scholar
• Kopsidas G, Roberts AS, Coia G, et al. In vitro improvement of a shark IgNAR antibody by Qbeta replicase mutation and ribosome display mimics in vivo affinity maturation. Immunol Lett 2006;107:163–168
   PubMed Web of Science ®Google Scholar
• Holz JB. The TITAN trial – assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012;46:343–346
   PubMed Web of Science ®Google Scholar
• Dooley H, Flajnik MF, Porter AJ. Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 2003;40:25–33
   PubMed Web of Science ®Google Scholar
• Siontorou CG. Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine 2013;8:4215–4227
   PubMed Web of Science ®Google Scholar
• Vaneycken I, Govaert J, Vincke C, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 2010;51:1099–1106
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010;2:256–265
   PubMed Web of Science ®Google Scholar
• Getts DR, Getts MT, McCarthy DP, et al. Have we overestimated the benefit of human(ized) antibodies? MAbs 2010;2:682–694
   PubMed Web of Science ®Google Scholar
• Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–1745
   PubMed Web of Science ®Google Scholar
• Bender NK, Heilig CE, Droll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269–274
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122–1126
   PubMed Web of Science ®Google Scholar
• Kim DY, To R, Kandalaft H, et al. Antibody light chain variable domains and their biophysically improved versions for human immunotherapy. MAbs 2014;6:219–235
   PubMed Web of Science ®Google Scholar
• Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003;325:531–553
   PubMed Web of Science ®Google Scholar
• Martin F, Volpari C, Steinkuhler C, et al. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng 1997;10:607–614
   PubMedGoogle Scholar
• Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nature Biotechnol 2004;22:1161–1165
   PubMed Web of Science ®Google Scholar
• To R, Hirama T, Arbabi-Ghahroudi M, et al. Isolation of monomeric human V(H)s by a phage selection. J Biol Chem 2005;280:41395–41403
   PubMed Web of Science ®Google Scholar
• Hussack G, Keklikian A, Alsughayyir J, et al. A V(L) single-domain antibody library shows a high-propensity to yield non-aggregating binders. PEDS 2012;25:313–318
   Google Scholar
• Söderlind E, Vergeles M, Borrebaeck CA. Domain libraries: synthetic diversity for de novo design of antibody V-regions. Gene 1995;160:269–272
   PubMed Web of Science ®Google Scholar
• van den Beucken T, van Neer N, Sablon E, et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol 2001;310:591–601
   PubMed Web of Science ®Google Scholar
• Paz K, Brennan LA, Iacolina M, et al. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Molec Cancer Ther 2005;4:1801–1809
   PubMed Web of Science ®Google Scholar
• Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Isolation of monoclonal antibody fragments from phage display libraries. Methods Mol Biol 2009;502:341–364
   PubMedGoogle Scholar
• Arbabi-Ghahroudi M, Mackenzie R, Tanha J. Site-directed mutagenesis for improving biophysical properties of VH domains. Methods Mol Biol 2010;634:309–330
   PubMedGoogle Scholar
• Kim DY, Hussack G, Kandalaft H, Tanha J. Mutational approaches to improve the biophysical properties of human single-domain antibodies. Biochim Biophys Acta 2014;1844:1983–2001
   PubMed Web of Science ®Google Scholar
• Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 2008;376:926–931
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnol 2005;23:1126–1136
   PubMed Web of Science ®Google Scholar
• Holland MC, Wurthner JU, Morley PJ, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol 2013;33:1192–1203
   PubMed Web of Science ®Google Scholar
• O'Connor-Semmes RL, Lin J, Hodge RJ, et al. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans–PK/PD and safety. Clin Pharmacol Therap 2014;96:704–712
   PubMed Web of Science ®Google Scholar
• Holt LJ, Basran A, Jones K, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. PEDS 2008;21:283–288
   Google Scholar
• Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFα domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs 2010;2:625–638
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Prabakaran P, et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 2014;88:1125–1139
   PubMed Web of Science ®Google Scholar
• Feng M, Gao W, Wang R, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 2013;110:E1083–E1091
   PubMed Web of Science ®Google Scholar
• Chen W, Feng Y, Zhao Q, et al. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Molec Cancer Therap 2012;11:1400–1410
   PubMed Web of Science ®Google Scholar
• Tang Z, Feng M, Gao W, et al. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Molec Cancer Therap 2013;12:416–426
   PubMed Web of Science ®Google Scholar
• Miao Q, Shang B, Ouyang Z, et al. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin. Sci China C Life Sci 2007;50:447–456
   PubMedGoogle Scholar
• Suchard SJ, Davis PM, Kansal S, et al. A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J. Immunol 2013;191:4599–4610
   PubMed Web of Science ®Google Scholar
• Gong R, Wang Y, Ying T, Dimitrov DS. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One 2012;7:e42288
   PubMed Web of Science ®Google Scholar
• Chen W, Gong R, Ying T, et al. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Curr Drug Discov Technol 2014;11:28–40
   PubMedGoogle Scholar
• Xiao X, Feng Y, Vu BK, et al. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 2009;387:387–392
   PubMed Web of Science ®Google Scholar
• Gong R, Wang Y, Feng Y, et al. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J Biol Chem 2011;286:27288–27293
   PubMed Web of Science ®Google Scholar
• Gehlsen K, Gong R, Bramhill D, et al. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs 2012;4:466–474
   PubMed Web of Science ®Google Scholar
• Ying T, Chen W, Feng Y, et al. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288:25154–25164
   PubMed Web of Science ®Google Scholar